Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron loading and its clinical implications.

Chaim Hershko1

  • 1Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel. hershko@ szmc.org.il

American Journal of Hematology
|October 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration.

American journal of hematology·2022
Same author

Hemochromatosis redefined.

Blood·2022
Same author

Plasma nontransferrin bound iron-nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation.

American journal of hematology·2021
Same author

Vaccine efficacy and iron deficiency: an intertwined pair?

The Lancet. Haematology·2021
Same author

Autoimmune gastritis.

Nature reviews. Disease primers·2020
Same author

Assessment of iron deficiency.

Haematologica·2019
Same journal

Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta-Thalassemia Trait.

American journal of hematology·2026
Same journal

POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.

American journal of hematology·2026
Same journal

EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.

American journal of hematology·2026
Same journal

Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count.

American journal of hematology·2026
Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026
See all related articles

Harmful iron overload occurs in genetic disorders and anemias due to regulatory protein defects. New noninvasive methods and continuous chelation therapies offer improved strategies to manage iron toxicity.

Area of Science:

  • Hematology
  • Medical Biochemistry
  • Pharmacology

Background:

  • Iron homeostasis is crucial, but defects in regulatory proteins like hepcidin or conditions like thalassemia and myelodysplastic syndromes can lead to harmful iron accumulation.
  • Nontransferrin-bound iron plays a significant role in disease pathogenesis, contributing to iron toxicity.

Purpose of the Study:

  • To summarize key aspects of iron loading and its clinical implications.
  • To highlight advancements in understanding and managing iron toxicity.

Main Methods:

  • Review of current literature on iron metabolism, disease pathogenesis, and treatment strategies.
  • Discussion of noninvasive methods for assessing iron accumulation and chelation efficacy.

Main Results:

Related Experiment Videos

  • Identification of specific patient groups at risk for iron overload.
  • Availability of accurate noninvasive methods for iron assessment.
  • Continuous chelation therapy, including combination therapy (deferoxamine and deferiprone) or deferasirox, offers optimal protection against iron toxicity.

Conclusions:

  • Understanding nontransferrin-bound iron's role is key to developing effective treatment strategies.
  • Continuous chelation therapy is essential for preventing and reversing iron toxicity.
  • Ongoing research will further clarify the role of oral and combination chelation therapies in managing iron overload disorders.